Clinical Trial Update: The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the impact of galantamine hydrobromide as an adjunct to electroconvulsive therapy on mood and cognitive outcomes in major depressive di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder
• Schizoaffective Disorder

Drugs mentioned

• Galantamine HBr (Reminyl) (galantamine hydrobromide)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Major Depression, Bipolar Depression | Phase 3 | Status: COMPLETED | Results posted: 2012-12-03